BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $ARGX readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04833894-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~ADAPT Jr readout (P2/3) · argenx $ARGX
DESCRIPTION:Evaluating the Pharmacokinetics\, Pharmacodynamics\, and Safety
  of Efgartigimod Administered Intravenously in Children With Generalized M
 yasthenia Gravis\n\nPrimary completion date: 2027-03 (estimated) — month
  only\, shown on the 1st\nOriginally planned: 2024-10-31 (+28.0 months)\nP
 hase 2/3 · Oncology · Generalized Myasthenia Gravis\nEnrollment: 15 · S
 ites: 25\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT04833894\nhttps://clinicaltrials.gov/study/NCT04833
 894
URL:https://datacutoff.com/radar.html?nct=NCT04833894
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655155-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~eSScape readout (P2) · argenx $ARGX
DESCRIPTION:A Study to Assess the Efficacy and Safety of Efgartigimod PH20 
 SC in Adults With Systemic Sclerosis\n\nPrimary completion date: 2027-03 (
 estimated) — month only\, shown on the 1st\nOriginally planned: 2026-08-
 17 (+6.4 months)\nPhase 2 · Immuno · Systemic Sclerosis (SSc)\nEnrollmen
 t: 87 · Sites: 79\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT06655155\nhttps://clinicaltrials.gov/stud
 y/NCT06655155
URL:https://datacutoff.com/radar.html?nct=NCT06655155
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04280718-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:ADHERE+ readout (P2) · argenx $ARGX
DESCRIPTION:A Study to Assess the Long-term Safety and Efficacy of a Subcut
 aneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Dem
 yelinating Polyneuropathy (CIDP\, an Autoim…\n\nPrimary completion date:
  2027-04-30 (estimated)\nOriginally planned: 2024-05-25 (+35.2 months)\nPh
 ase 2 · Neuro · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
 \nEnrollment: 229 · Sites: 147\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT04280718\nhttps://clinicaltr
 ials.gov/study/NCT04280718
URL:https://datacutoff.com/radar.html?nct=NCT04280718
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684847-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~Unity readout (P3) · argenx $ARGX
DESCRIPTION:A Study of the Efficacy and Safety of Efgartigimod in Patients 
 With Primary Sjögren's Syndrome\n\nPrimary completion date: 2027-07 (esti
 mated) — month only\, shown on the 1st\nPhase 3 · Immuno · Primary Sjo
 grens Disease\nEnrollment: 631 · Sites: 303\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06684847\nhttps
 ://clinicaltrials.gov/study/NCT06684847
URL:https://datacutoff.com/radar.html?nct=NCT06684847
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06392386-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~ADAPT Jr SC readout (P2/3) · argenx $ARGX
DESCRIPTION:A Study of Efgartigimod PH20 SC in Children Between 2 and Less 
 Than 18 Years of Age With Generalized Myasthenia Gravis\n\nPrimary complet
 ion date: 2027-09 (estimated) — month only\, shown on the 1st\nOriginall
 y planned: 2026-09-30 (+11.0 months)\nPhase 2/3 · Oncology · Generalized
  Myasthenia Gravis\nEnrollment: 12 · Sites: 22\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06392386\nht
 tps://clinicaltrials.gov/study/NCT06392386
URL:https://datacutoff.com/radar.html?nct=NCT06392386
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920004-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~emvigorate readout (P3) · argenx $ARGX
DESCRIPTION:A Study to Assess Efficacy and Safety of Empasiprubart Versus I
 VIg in Adults With CIDP\n\nPrimary completion date: 2027-09 (estimated) 
 — month only\, shown on the 1st\nOriginally planned: 2027-05 (+4.0 month
 s)\nPhase 3 · Neuro · Chronic Inflammatory Demyelinating Polyneuropathy\
 , CIDP\, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nEnrollm
 ent: 218 · Sites: 109\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT06920004\nhttps://clinicaltrials.gov/
 study/NCT06920004
URL:https://datacutoff.com/radar.html?nct=NCT06920004
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812925-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~ADVANCE SC+ readout (P3) · argenx $ARGX
DESCRIPTION:A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartig
 imod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytope
 nia\n\nPrimary completion date: 2027-10 (estimated) — month only\, shown
  on the 1st\nOriginally planned: 2026-10-01 (+12.0 months)\nPhase 3 · Car
 dio-Met · Primary Immune Thrombocytopenia\nEnrollment: 173 · Sites: 83\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT04812925\nhttps://clinicaltrials.gov/study/NCT04812925
URL:https://datacutoff.com/radar.html?nct=NCT04812925
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673627-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~ADAPT Forward2 readout (P2) · argenx $ARGX
DESCRIPTION:ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety\, Toler
 ability and Efficacy of Empasiprubart IV Monotherapy in Participants With 
 AChR-Ab Seropositive Generalized Myasthenia…\n\nPrimary completion date:
  2027-10 (estimated) — month only\, shown on the 1st\nPhase 2 · Oncolog
 y · AChR-Ab Seropositive Generalized Myasthenia Gravis\, Myasthenia Gravi
 s (MG)\, MG - Myasthenia Gravis\nEnrollment: 40 · Sites: 19\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T07673627\nhttps://clinicaltrials.gov/study/NCT07673627
URL:https://datacutoff.com/radar.html?nct=NCT07673627
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07091630-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:emnergize readout (P3) · argenx $ARGX
DESCRIPTION:A Study to Assess the Efficacy and Safety of Empasiprubart in A
 dults With CIDP\n\nPrimary completion date: 2027-10-07 (estimated)\nPhase 
 3 · Neuro · Chronic Inflammatory Demyelinating Polyneuropathy\, CIDP\, C
 hronic Inflammatory Demyelinating Polyradiculoneuropathy\nEnrollment: 160 
 · Sites: 95\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT07091630\nhttps://clinicaltrials.gov/study/NCT0
 7091630
URL:https://datacutoff.com/radar.html?nct=NCT07091630
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503731-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~Shamrock readout (P2) · argenx $ARGX
DESCRIPTION:A Study to Evaluate the Safety and Tolerability of Efgartigimod
  PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With A
 ntibody-Mediated Rejection (AMR)\n\nPrimary completion date: 2027-11 (esti
 mated) — month only\, shown on the 1st\nOriginally planned: 2027-09 (+2.
 0 months)\nPhase 2 · Other · Antibody-mediated Rejection\nEnrollment: 33
  · Sites: 23\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://datac
 utoff.com/radar.html?nct=NCT06503731\nhttps://clinicaltrials.gov/study/NCT
 06503731
URL:https://datacutoff.com/radar.html?nct=NCT06503731
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
